Report Type
Single Stock Research Reports
Recent single stock reports highlight a recurring theme of solid top-line performance paired with aggressive strategic reinvestment, though varied operational headwinds are impacting near-term profitability across sectors. Veralto and Fluence Energy reported revenue largely in line with expectations, yet experienced contrasting margin outcomes; Veralto achieved a 24.6% operating margin beat, while Fluence's gross margins were compressed to 5.6% due to project-specific cost overruns. In the technology space, Alphabet’s massive AI build-out is reflected in 2026 Capex guidance of $175-185 billion, a shift that is forcing analysts to abandon free cash flow yield in favor of P/E and EBITDA valuation frameworks. Growth outlooks remain cautious, with Match Group signaling softer 2026 revenue due to regulatory costs and Veralto projecting moderate sales growth between LSD+ and MSD+. Macroeconomic risks are also tempering sentiment, as evidenced by downgrades for Harbour Energy driven by anticipated 2026 LNG oversupply and high leverage. Collectively, these reports underscore a market environment where robust demand and backlogs, such as Fluence’s $5.5 billion, must be weighed against rising capital intensity and shifting valuation metrics.
578 reports available
All reports
Page 23 of 25
LY Corp 4Q Earnings
Goldman Sachs · May 11, 2026
Oscar Health 1Q26 Recap Hix Margin Comfort Affirmed Post Oep Growth Burst
Goldman Sachs · May 11, 2026
ITT Inc. FY26 Guide Conservative
Goldman Sachs · May 11, 2026
Firefly Aerospace Launch Progress
Goldman Sachs · May 11, 2026
Shift4 Payments 1Q26 Takeaways
Goldman Sachs · May 11, 2026
CSL First Take FY26 Trading Downgrade
Goldman Sachs · May 11, 2026
Deutsche Bank Updating Estimates Post Q1 2026
Goldman Sachs · May 11, 2026
Capacity Expansion Plans and Direct Customer Investment
Goldman Sachs · May 11, 2026
Assessing the Potential Impact of New Hospital in Amaravati Market
Goldman Sachs · May 11, 2026
MetaX GPU Ramp Up and 1Q26 Earnings Update
Goldman Sachs · May 11, 2026
Metcash Preliminary FY26 Conference Call Key Points
Goldman Sachs · May 11, 2026
MoonLake Immunotherapeutics 1Q26 Earnings Update
Goldman Sachs · May 11, 2026
User Terminal in Expansion
Goldman Sachs · May 11, 2026
Vista Energy New 2026-30 Outlook Unveiled
Goldman Sachs · May 11, 2026
Bicara Therapeutics 1Q26 Earnings Update
Goldman Sachs · May 11, 2026
Embraer Continues Strong Revenue Growth and Margin Trajectory
Goldman Sachs · May 11, 2026
Nemetschek: Growth Momentum Continues in Core Segments
Goldman Sachs · May 11, 2026
Clariant Revising Estimates Post 1Q26
Goldman Sachs · May 11, 2026
Upwork Q1 2026 Review
Goldman Sachs · May 11, 2026
FAQs on the Evergreen Business
Goldman Sachs · May 11, 2026
Intellia Therapeutics: Hereditary Angioedema BLA Completion and ATTR Study Updates
Goldman Sachs · May 11, 2026
Flynas Co 1Q26 First Take
Goldman Sachs · May 11, 2026
Arxis Company Analysis and Buy Initiation
Goldman Sachs & Co. LLC · May 11, 2026
Looking for R&D Levers
Goldman Sachs · May 11, 2026